Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Laryngoscope ; 2024 Apr 23.
Article in English | MEDLINE | ID: mdl-38651382

ABSTRACT

OBJECTIVE: The modified frailty index (mFI-5) is a National Surgical Quality Improvement Program-derived 5-factor index that has been proven to reflect frailty and predict morbidity and mortality. We hypothesize that mFI-5 is a valid predictive measure in the transoral robotic surgery (TORS) population. METHODS: Retrospective study utilizing the TriNetX US-collaborative health records network querying for TORS patients. Cohorts were stratified by mFI-5 score which uses five ICD-10 codes: nonindependent functional status, hypertension, obstructive respiratory disease, heart failure, and diabetes mellitus. Cohorts were matched by age using propensity score matching. Outcome measures included survival, infection, pneumonia, tracheostomy dependence, and percutaneous endoscopic gastrostomy dependence. Reported odds ratios were normalized to mFI-5 = 0. RESULTS: A total of 9,081 patients were included in the final analysis. Greater mFI-5 scores predicted decreased survival and increased incidence of postoperative infection and pneumonia. Odds of 5-year mortality were 1.93 (p = 0.0003) for mFI-5 = 2 and 1.90 (p = 0.0002) for mFI-5 = 3. Odds of 2-year mortality were 1.25 (p = 0.0125) for mFI-5 = 1, 1.58 (p = 0.0002) for mFI-5 = 2, and 1.87 (p = 0.003) for mFI-5 = 3. Odds of postoperative infection were 1.51 (p = 0.02) for mFI-5 = 2 and 1.78 (p = 0.05) for mFI-5 = 3. Two-year odds of developing pneumonia were 1.69 (p = 0.0001) for mFI-5 = 2 and 2.84 (p < 0.0001) for mFI-5 = 3. Two-month odds of pneumonia were 1.50 (p = 0.0259) for mFI-5 = 2 and 2.55 (p = 0.0037) for mFI-5 = 3. mFI-5 = 4 or 5 had too few patients to analyze. Using polynomial regression to model age versus incident 5-year post-TORS death (R2 = 0.99), mFI-5 scores better predicted survival than age alone. CONCLUSION: This study demonstrates that mFI-5 predicts mortality, pneumonia, and postoperative infection independently of age. LEVEL OF EVIDENCE: 4 Laryngoscope, 2024.

2.
Am Surg ; 90(6): 1800-1802, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38565170

ABSTRACT

Laparoscopic subtotal cholecystectomy (LSC) is utilized to prevent complications in the difficult cholecystectomy. Medium-term outcomes are poorly studied for fenestrating and reconstituting operative techniques. A single-institution retrospective review was undertaken of all LSCs. A telephone survey was used to identify complications addressed at other institutions. We performed subgroup analyses by operative approach and of patients requiring postoperative endoscopic intervention (ERC). 28 patients met inclusion criteria. The median follow-up was 32.7 months. There were no bile duct injuries or reoperations. 21% of patients required a postoperative ERC and 50% were discharged home with a drain. Bile leaks were found to be more prevalent in the fenestrating LSC group (38% vs 0%, P = .003). The case series suggested more severe recurrent biliary disease in patients undergoing reconstituting LSC. Laparoscopic subtotal cholecystectomy appears to have satisfactory medium-term outcomes. The reconstituting LSC group trends toward more severe recurrent disease which warrants further investigation.


Subject(s)
Cholecystectomy, Laparoscopic , Patient Discharge , Postoperative Complications , Humans , Cholecystectomy, Laparoscopic/methods , Cholecystectomy, Laparoscopic/adverse effects , Retrospective Studies , Female , Male , Follow-Up Studies , Middle Aged , Postoperative Complications/epidemiology , Adult , Treatment Outcome , Aged , Recurrence , Reoperation/statistics & numerical data
3.
Consult Pharm ; 24(7): 538-43, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19689182

ABSTRACT

The patient is an 88-year-old male who presented to a weekly pharmacy-run blood pressure (BP) screening at the retirement community where he resides. His past medical history consists of hypertension, hyperlipidemia, and altitude sickness. The patient's BP was 122/48 mmHg, which was lower than his average (148/64 mmHg). The patient was asked a series of questions to determine the cause of the BP decline. He commented that he does not drink much water, stating, "It tastes bad." The patient started acetazolamide six years ago for treatment of altitude sickness and it was suspected that this was contributing to the patient's taste disturbance. The pharmacist apprised the physician that the patient was experiencing a probable adverse effect from a medication and then developed a program to taper the medication based on the pharmacokinetics of the drug. After the drug was completely tapered off, the patient reported that not only had his sense of taste returned to normal, but his cognition had improved as well. He previously could not perform some of his instrumental activities of daily living without help, but now believes he can continue to live independently. He reported no dizzy spells since discontinuing the medication and his BP has remained stable.


Subject(s)
Acetazolamide/adverse effects , Carbonic Anhydrase Inhibitors/adverse effects , Dysgeusia/chemically induced , Acetazolamide/pharmacokinetics , Activities of Daily Living , Aged, 80 and over , Blood Pressure , Carbonic Anhydrase Inhibitors/pharmacokinetics , Cognition/drug effects , Drinking Behavior , Humans , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...